title: Arginase inhibition by piceatannol-3'-O-β-D-glucopyranoside improves endothelial dysfunction via activation of endothelial nitric oxide synthase in ApoE-null mice fed a high-cholesterol diet.
abstract: Elevated plasma cholesterol is a hallmark of numerous cardiovascular diseases that are closely linked to endothelial dysfunction indicating decreased nitric oxide (NO) production in the endothelium. It has been previously demonstrated that piceatannol-3'-O-β-D-glucopyranoside (PG) inhibits arginase activity and reciprocally regulates NO production. Here, we aimed to ascertain whether PG ameliorates vascular function in wild-type (WT) and atherogenic model mice [apolipoprotein E-null mice (ApoE-/-)] and to investigate the possible underlying mechanism. Preincubation of aortic vessels from WT mice fed a normal diet (ND) with PG attenuated vasoconstriction response to U46619 and phenylephrine (PE), while the vasorelaxant response to acetylcholine (Ach) was markedly enhanced in an endothelium-dependent manner. However, the endothelium-independent NO donor, sodium nitroprusside (SNP), did not change vessel reactivity. In thoracic aorta from ApoE-/- mice, a high-cholesterol diet (HCD) induced an increase in arginase activity, a decrease in NO release and an increase in reactive oxygen species generation that was reversed by treatment with PG. The effect of PG was associated with enhanced stability of the eNOS dimer and was not dependent on the expression levels of arginase II and eNOS proteins, although eNOS expression was increased in ApoE-/- mice fed an HCD. Furthermore, PG treatment attenuated the PE-dependent contractile response, and significantly improved the Ach-dependent vasorelaxation response in aortic rings from ApoE-/- mice fed an HCD. On the other hand, PG incubation neither altered the contractile response to a high K+ solution nor the relaxation response to SNP. When analyzing the L-arginine content using high-performance liquid chromatography, PG incubation increased the intracellular L-arginine concentration. PG administration in the drinking water significantly reduced fatty streak formation in ApoE-/- mice fed an HCD. These data indicate that PG improves the pathophysiology of cholesterol-mediated endothelial dysfunction. Therefore, we conclude that the development of PG as a novel effective therapy for preventing atherosclerotic diseases is warranted.
authors: Department of Biology, Kangwon National University, Chuncheon 200-701, Republic of Korea.
authors: Ainieng
authors: A
authors: Woo
authors: Woosung
authors: W
authors: Shin
authors: To Dao
authors: TD
authors: Cuong
authors: Byungsun
authors: B
authors: Min
authors: Jeong Hyung
authors: JH
authors: Lee
authors: Byung Hwa
authors: BH
authors: Jeon
authors: Sungwoo
authors: S
authors: Ryoo
mesh_terms: D000704:Analysis of Variance; D000818:Animals; D001011:Aorta / Q000187:drug effects / Q000502:physiology; D001057:Apolipoproteins E / Q000235:genetics / Q000378:metabolism*; D001119:Arginase / Q000037:antagonists & inhibitors* / Q000378:metabolism; D059305:Diet, High-Fat; D004795:Enzyme Stability / Q000187:drug effects; D005960:Glucosides / Q000494:pharmacology*; D008297:Male; D051379:Mice; D018345:Mice, Knockout; D052250:Nitric Oxide Synthase Type III / Q000737:chemistry / Q000187:drug effects / Q000378:metabolism*; D058226:Plaque, Atherosclerotic / Q000473:pathology; D013267:Stilbenes / Q000494:pharmacology*; D014661:Vasoconstriction / Q000187:drug effects
chemical_list: D001057:Apolipoproteins E; D005960:Glucosides; D013267:Stilbenes; C554087:piceatannol-3'-O-glucopyranoside; D052250:Nitric Oxide Synthase Type III; D001119:Arginase